Alkermes to initiate second Phase III study of ALKS 3831 for schizophrenia
Alkermes initiates phase 1 clinical study of new CNS drug candidate
Alkermes achieves milestones for CNS medicines
Alkermes reports third quarter 2015 financial results
FDA approves Aristada for treatment of schizophrenia
Alkermes to sell manufacturing plant at Gainesville, GA to Recro Pharma
Alkermes appoints Senior Vice President of Research, Pharmaceutical and Non-clinical Development
Alkermes receives Notices of Allowance for US patents for four CNS pipeline candidates
Join Alkermes Contract Pharma Services at CpHI/ICSE meeting at booth 1D19
Alkermes announces initiation of Phase 1 clinical study of ALKS 7106 for treatment of pain
Alkermes submits NDA to FDA for aripiprazole lauroxil for treatment of schizophrenia
Alkermes initiates FORWARD-5 clinical study of ALKS 5461
Alkermes initiates Phase I Clinical Study of ALKS 8700 for treatment of multiple sclerosis
Alkermes to initiate second Phase 2 clinical study of novel broad-spectrum oral antipsychotic
Alkermes to present data on new medicines in development for schizophrenia and depression
